Nanoplatform based on carbon nanoparticles loaded with doxorubicin enhances apoptosis by generating reactive oxygen species for effective cancer therapy

Liu,Yusheng; Zhang,Junfeng; Wu,Chunying; Lai,Yigui; Fan,Huijie; Wang,Qiang; Lin,Zhaolin; Chen,Jishang; Zhao,Xiaoshan; Jiang,Xuefeng

doi:10.3892/ol.2024.14421

Nanoplatform based on carbon nanoparticles loaded with doxorubicin enhances apoptosis by generating reactive oxygen species for effective cancer therapy

Authors:
- Yusheng Liu
- Junfeng Zhang
- Chunying Wu
- Yigui Lai
- Huijie Fan
- Qiang Wang
- Zhaolin Lin
- Jishang Chen
- Xiaoshan Zhao
- Xuefeng Jiang
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, Yangjiang People's Hospital, Yangjiang, Guangdong 529500, P.R. China
Published online on: April 30, 2024 https://doi.org/10.3892/ol.2024.14421
Article Number: 288
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

At present, due to its wide application and relatively low cost, chemotherapy remains a clinically important cancer treatment option; however, a number of chemotherapeutic drugs have important limitations, such as lack of specificity, high toxicity and side effects, and multi‑drug resistance. The emergence of nanocarriers has removed numerous clinical application limitations of certain antitumor chemotherapy drugs and has been widely used in the treatment of tumors with nanodrugs. The present study used carbon nanoparticles (CNPs) as a nanocarrier for doxorubicin (DOX) to form the novel nanomedicine delivery system (CNPs@DOX)was demonstrated by UV‑vis and fluorescence spectrophotometry, ζ potential and TEM characterization experiments. The results confirmed the successful preparation of CNPs@DOX nanoparticles with a particle size of 96±17 nm, a wide range of absorption and a negatively charged surface. Furthermore, CNPs@DOX produced more reactive oxygen species and induced apoptosis, and thus exhibited higher cytotoxicity than DOX, which is a small molecule anticancer drug without a nanocarrier delivery system.. The present study provides a strategy for the treatment of tumors with nanomedicine.

View Figures

View References

1	Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, Zhou Z, Yin P and Zhou M: National and subnational trends in cancer burden in China, 2005-20: An analysis of national mortality surveillance data. Lancet Public Health. 8:e943–e955. 2023. View Article : Google Scholar : PubMed/NCBI
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
4	Lin L, Li Z, Yan L, Liu Y, Yang H and Li H: Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019. J Hematol Oncol. 14:1972021. View Article : Google Scholar : PubMed/NCBI
5	Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, Moghaddam LK, Paschepari SR, Azizi H, Torkamandi S and Tavakkoly-Bazzaz J: New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther. 24:233–243. 2017. View Article : Google Scholar : PubMed/NCBI
6	Cao J, Huang D and Peppas NA: Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites. Adv Drug Deliv Rev. 167:170–188. 2020. View Article : Google Scholar : PubMed/NCBI
7	Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW and Porter CJ: Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 65:315–499. 2013. View Article : Google Scholar : PubMed/NCBI
8	Tang L, Jiang W, Wu L, Yu X, He Z, Shan W, Fu L, Zhang Z and Zhao Y: TPGS2000-DOX prodrug micelles for improving breast cancer therapy. Int J Nanomedicine. 16:7875–7890. 2021. View Article : Google Scholar : PubMed/NCBI
9	Wu Y, Wang Z, Han L, Guo Z, Yan B, Guo L, Zhao H, Wei M, Hou N, Ye J, et al: PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer. Mol Ther. 30:2603–2617. 2022. View Article : Google Scholar : PubMed/NCBI
10	Etrych T, Daumová L, Pokorná E, Tušková D, Lidický O, Kolářová V, Pankrác J, Šefc L, Chytil P and Klener P: Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging. J Control Release. 289:44–55. 2018. View Article : Google Scholar : PubMed/NCBI
11	Yan D, Wei H, Lai X, Ge Y, Xu S, Meng J, Wen T, Liu J, Zhang W, Wang J and Xu H: Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia. J Control Release. 327:766–778. 2020. View Article : Google Scholar : PubMed/NCBI
12	Almajidi YQ, Kadhim MM, Alsaikhan F, Turki Jalil A, Hassan Sayyid N, Alexis Ramírez-Coronel A, Hassan Jawhar Z, Gupta J, Nabavi N, Yu W and Ertas YN: Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. Environ Res. 227:1157222023. View Article : Google Scholar : PubMed/NCBI
13	Hong Y, Che S, Hui B, Yang Y, Wang X, Zhang X, Qiang Y and Ma H: Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine. Biomed Pharmacother. 112:1086142019. View Article : Google Scholar : PubMed/NCBI
14	Zhu L and Lin M: The synthesis of nano-doxorubicin and its anticancer effect. Anticancer Agents Med Chem. 21:2466–2477. 2021. View Article : Google Scholar : PubMed/NCBI
15	Fernandez-Fernandez A, Manchanda R and McGoron AJ: Theranostic applications of nanomaterials in cancer: Drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol. 165:1628–1651. 2011. View Article : Google Scholar : PubMed/NCBI
16	Zhang J, Yin X, Li C, Yin X, Xue Q, Ding L, Ju J, Ma J, Zhu Y, Du D, et al: A Multifunctional Photoacoustic/Fluorescence Dual-Mode-Imaging Gold-Based Theranostic Nanoformulation without External Laser Limitations. Adv Mater. 34:e21106902022. View Article : Google Scholar : PubMed/NCBI
17	Patel SC, Lee S, Lalwani G, Suhrland C, Chowdhury SM and Sitharaman B: Graphene-based platforms for cancer therapeutics. Ther Deliv. 7:101–116. 2016. View Article : Google Scholar : PubMed/NCBI
18	Lin J, Chen X and Huang P: Graphene-based nanomaterials for bioimaging. Adv Drug Deliv Rev. 105((Pt B)): 242–254. 2016. View Article : Google Scholar : PubMed/NCBI
19	Zhao H, Ding R, Zhao X, Li Y, Qu L, Pei H, Yildirimer L, Wu Z and Zhang W: Graphene-based nanomaterials for drug and/or gene delivery, bioimaging, and tissue engineering. Drug Discov Today. 22:1302–1317. 2017. View Article : Google Scholar : PubMed/NCBI
20	Díez-Pascual AM: Carbon-Based Nanomaterials. Int J Mol Sci. 22:77262021. View Article : Google Scholar : PubMed/NCBI
21	Oh B and Lee CH: Development of thiolated-graphene quantum dots for regulation of ROS in macrophages. Pharm Res. 33:2736–2747. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zhang J, Chen L, Shen B, Chen L, Mo J and Feng J: Dual-Sensitive graphene oxide loaded with proapoptotic peptides and anticancer drugs for cancer synergetic therapy. Langmuir. 35:6120–6128. 2019. View Article : Google Scholar : PubMed/NCBI
23	Sharifi S, Behzadi S, Laurent S, Forrest ML, Stroeve P and Mahmoudi M: Toxicity of nanomaterials. Chem Soc Rev. 41:2323–2343. 2012. View Article : Google Scholar : PubMed/NCBI
24	Guan M, Li J, Jia Q, Ge J, Chen D, Zhou Y, Wang P, Zou T, Zhen M, Wang C and Shu C: A versatile and clearable nanocarbon theranostic based on carbon dots and gadolinium metallofullerene nanocrystals. Adv Healthc Mater. 5:2283–2294. 2016. View Article : Google Scholar : PubMed/NCBI
25	Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R and Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751–760. 2007. View Article : Google Scholar : PubMed/NCBI
26	Yuan Y, Cai T, Xia X, Zhang R, Chiba P and Cai Y: Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer. Drug Deliv. 23:3350–3357. 2016. View Article : Google Scholar : PubMed/NCBI
27	Donahue ND, Acar H and Wilhelm S: Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv Drug Deliv Rev. 143:68–96. 2019. View Article : Google Scholar : PubMed/NCBI
28	Li R, Wang Y, Du J, Wang X, Duan A, Gao R, Liu J and Li B: Graphene oxide loaded with tumor-targeted peptide and anti-cancer drugs for cancer target therapy. Sci Rep. 11:17252021. View Article : Google Scholar : PubMed/NCBI
29	Cagel M, Grotz E, Bernabeu E, Moretton MA and Chiappetta DA: Doxorubicin: Nanotechnological overviews from bench to bedside. Drug Discov Today. 22:270–281. 2017. View Article : Google Scholar : PubMed/NCBI
30	Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE and Altman RB: Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics. 21:440–446. 2011. View Article : Google Scholar : PubMed/NCBI
31	Chen K, Cai H, Zhang H, Zhu H, Gu Z, Gong Q and Luo K: Stimuli-responsive polymer-doxorubicin conjugate: Antitumor mechanism and potential as nano-prodrug. Acta Biomater. 84:339–355. 2019. View Article : Google Scholar : PubMed/NCBI
32	Dharmaraja AT: Role of reactive oxygen species (ROS) in therapeutics and drug resistance in cancer and bacteria. J Med Chem. 60:3221–3240. 2017. View Article : Google Scholar : PubMed/NCBI
33	Cheung EC and Vousden KH: The role of ROS in tumour development and progression. Nat Rev Cancer. 22:280–297. 2022. View Article : Google Scholar : PubMed/NCBI
34	Sp N, Kang DY, Jo ES, Rugamba A, Kim WS, Park YM, Hwang DY, Yoo JS, Liu Q, Jang KJ and Yang YM: Tannic Acid Promotes TRAIL-Induced extrinsic apoptosis by regulating mitochondrial ROS in human embryonic carcinoma cells. Cells. 9:2822020. View Article : Google Scholar : PubMed/NCBI
35	Yao W, Lin Z, Shi P, Chen B, Wang G, Huang J, Sui Y, Liu Q, Li S, Lin X, et al: Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells. Biochem Pharmacol. 171:1136802020. View Article : Google Scholar : PubMed/NCBI